Design Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q2 2026). Net income: −$71M, trailing twelve months to Q2 2026. Free cash flow: −$55M, trailing twelve months to Q2 2026. EPS: −$1.18, trailing twelve months to Q2 2026.

DSGNDesign Therapeutics, Inc.

Healthcare

$11.49+77% 1Y

$11.49

$5.5352 weeks$15.94

DSGN as reported

Design Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Net income: −$71M
Net income · +12% year on year · trailing twelve months to Q2 2026
Free cash flow: −$55M
Free cash flow · +8.5% year on year · trailing twelve months to Q2 2026
EPS: −$1.18
EPS · +5.4% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DSGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q2 2026
Net income	−$71M	+12%	Q2 2026
EPS	−$1.18	+5.4%	Q2 2026
ROE	−33%	n/a	Q2 2026
ROA	−31%	n/a	Q2 2026
Free cash flow	−$55M	+8.5%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.